Skip to main content
SpringerLink
Log in
Book cover

Gastrointestinal Cancer pp 271–298Cite as

Gastrointestinal Stromal Tumors

  • Chapter

  • 914 Accesses

Part of the book series: M. D. Anderson Cancer Care Series ((MDCCS))

Chapter Overview

Over the past 60 years, basic scientists, pathologists, and clinical investigators have studied gastrointestinal stromal tumors (GISTs), with no major advances in patient care. Recent discoveries have led to an understanding of the biological role of Kit in GISTs and the development of one of the most exciting examples of targeted therapy to date. The success of the Kit tyrosine kinase inhibitor imatinib mesylate (Gleevec) has caught the attention of the medical community. Understanding the mechanisms of response and resistance to imatinib will broaden our understanding of cancer biology and lead to strategic approaches in the treatment of other malignancies. This understanding will take place more rapidly with faster patient accrual to clinical trials, such as those designed at M. D. Anderson Cancer Center. Thus, all oncologists should do their best to place their patients with GISTs on clinical trials.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Readings

  • Bauer S, Corless CL, Heinrich MC, et al. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003;51:261–265.

    PubMed  Google Scholar 

  • Bilimoria MM, Holtz DJ, Mirza NQ, et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer 2002;94:2441–2446.

    Article  PubMed  Google Scholar 

  • Blanke C. Evaluation of the molecularly targeted therapy STI571 in patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [abstract]. Proc Am Soc Clin Oncol 2001;20. Abstract 1.

    Google Scholar 

  • Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 1999;74:543–552.

    Article  PubMed  CAS  Google Scholar 

  • Carney JA, Sheps SG, Go VL, et al. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 1977;296:1517–1518.

    Article  PubMed  CAS  Google Scholar 

  • Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 2002;108:132–139.

    Article  PubMed  Google Scholar 

  • Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567–1572.

    PubMed  CAS  Google Scholar 

  • DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51–58.

    Article  PubMed  CAS  Google Scholar 

  • de Silva MV, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 2003;9:13–19.

    Article  PubMed  Google Scholar 

  • Edmonson J, Marks R, Buckner J, et al. Contrast of response to D-MAP + sargramostatin between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Proc Am Soc Clin Oncol 1999;18:541a.

    Google Scholar 

  • Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999;6:645–650.

    Article  PubMed  CAS  Google Scholar 

  • Ernst SI, Hubbs AE, Przygodzki RM, et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998;78:1633–1636.

    PubMed  CAS  Google Scholar 

  • Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 1985;56:2242–2250.

    Article  PubMed  CAS  Google Scholar 

  • Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002;10:81–89.

    Article  PubMed  Google Scholar 

  • Gottlieb J, Baker L, O’Bryan R, et al. Adriamycin (NSC-123-127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemotherapy Reports 1974;6:271–282.

    Google Scholar 

  • Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.

    Google Scholar 

  • Greenson JK. Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol 2003;16:366–375.

    Article  PubMed  Google Scholar 

  • Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484–495.

    Article  PubMed  CAS  Google Scholar 

  • Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–580.

    Article  PubMed  CAS  Google Scholar 

  • Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002;122:1493–1499.

    Article  PubMed  Google Scholar 

  • Hirota S, Okazaki T, Kitamura Y, et al. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am J Surg Pathol 2000;24:326–327.

    Article  PubMed  CAS  Google Scholar 

  • Isozaki K, Terris B, Belghiti J, et al. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000;157:1581–1585.

    PubMed  CAS  Google Scholar 

  • Judson I, Verweij J, van Oosterom A, et al. Imatinib (Gleevec) an active agent for gastrointestinal stromal tumors (GIST), but not for other soft tissue sarcoma (STS) subtypes not characterized for KIT and PDGF-R expression. Results of EORTC phase II studies [abstract]. Proc Am Soc Clin Oncol 2002. Abstract 1609.

    Google Scholar 

  • Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53–60.

    PubMed  CAS  Google Scholar 

  • Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001;120:210–215.

    PubMed  CAS  Google Scholar 

  • Mavligit GM, Zukwiski AA, Ellis LM, Chuang VP, Wallace S. Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer 1995;75:2083–2088.

    Article  PubMed  CAS  Google Scholar 

  • Miettinen M, Sarlomo-Rikala M, Lasota J. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol 2000b;13:536–541.

    Article  PubMed  CAS  Google Scholar 

  • Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000a;13:1134–1142.

    Article  PubMed  CAS  Google Scholar 

  • Miettinen R, Pitkanen A, Miettinen M. Are desmoid tumors kit positive? [comment]. J Comp Neurol 2001;432:440–465.

    Article  PubMed  Google Scholar 

  • Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992a;215:68–77.

    Article  PubMed  CAS  Google Scholar 

  • Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992b;69:1334–1341.

    Article  PubMed  CAS  Google Scholar 

  • Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998;19:323–324.

    Article  PubMed  CAS  Google Scholar 

  • Nocka K, Majumder S, Chabot B, et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice-evidence for an impaired c-kit kinase in mutant mice. Genes Dev 1989;3:816–826.

    Article  PubMed  CAS  Google Scholar 

  • Patel S, Legha S, Salem P, et al. Evaluation of ifosfamide in metastatic leiomyosarcomas of gastrointestinal origin. Proc Am Soc Clin Oncol 1991;31:352.

    Google Scholar 

  • Plager C, Papadopolous N, Salem P, et al. Adriamycin based chemotherapy for leiomyosarcoma of the stomach and small bowel [abstract]. Proc Am Soc Clin Oncol 1991;10:352.

    Google Scholar 

  • Rajan DK, Soulen MC, Clark TW, et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Intervent Radiol 2001;12:187–193.

    Article  CAS  Google Scholar 

  • Remmelink M, Decaestecker C, Darro F, et al. The in vitro influence of eight hormones and growth factors on the proliferation of eight sarcoma cell lines. J Cancer Res Clin Oncol 1998;124:155–164.

    Article  PubMed  CAS  Google Scholar 

  • Ricotti E, Fagioli F, Garelli E, et al. c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 1998;91:2397–2405.

    PubMed  CAS  Google Scholar 

  • Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118–8121.

    PubMed  CAS  Google Scholar 

  • Ruddon R. Cancer Biology. New York, NY: Oxford University Press; 1995.

    Google Scholar 

  • Sakurai S, Fukasawa T, Chong JM, et al. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal). Jpn J Cancer Res 1999; 90:1321–1328.

    PubMed  CAS  Google Scholar 

  • Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211–225.

    Article  PubMed  CAS  Google Scholar 

  • Shidham VB, Chivukula M, Gupta D, et al. Immunohistochemical comparison of gastrointestinal stromal tumor and solitary fibrous tumor. Arch Pathol Lab Med 2002;126:1189–1192.

    PubMed  Google Scholar 

  • Sjogren H, Meis-Kindblom JM, Stenman G, et al. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002;160:15–22.

    PubMed  Google Scholar 

  • Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297–4300.

    PubMed  CAS  Google Scholar 

  • Van den Abbeele A, Badawi R, Cliche J-P, et al. 18F-FDG PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST) [abstract]. Proc Am Soc Clin Oncol 2002. Abstract 1610.

    Google Scholar 

  • Van Oosterom A, Judson I, Verweij J. STI57, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study [abstract]. Proc Am Soc Clin Oncol 2001;20:1a. Abstract 2.

    Google Scholar 

  • von Mehren M, Blanke C, Joensuu H, et al. High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs) [abstract]. Proc Am Soc Clin Oncol 2002. Abstract 1608.

    Google Scholar 

  • Yantiss RK. Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. Am J Surg Pathol 2000;24:947–957.

    Article  PubMed  CAS  Google Scholar 

  • Zhang W, Stoica G, Tasca SI, et al. Modulation of tumor angiogenesis by stem cell factor. Cancer Res 2000;60:6757–6762.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, USA

    Dejka M. Steinert MD (Fellow) & Jonathan Trent MD, PhD (Assistant Professor)

Authors
  1. Dejka M. Steinert MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Trent MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030-4009, USA

    Jaffer A. Ajani MD

  2. Department of Gastrointestinal Medicine and Nutrition, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030-4009, USA

    Patrick M. Lynch MD, JD

  3. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030-4009, USA

    Nora A. Janjan MD

  4. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030-4009, USA

    Steven A. Curley MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Steinert, D.M., Trent, J. (2005). Gastrointestinal Stromal Tumors. In: Ajani, J.A., Lynch, P.M., Janjan, N.A., Curley, S.A. (eds) Gastrointestinal Cancer. M. D. Anderson Cancer Care Series. Springer, New York, NY. https://doi.org/10.1007/0-387-27285-2_17

Download citation

  • DOI: https://doi.org/10.1007/0-387-27285-2_17

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-22090-1

  • Online ISBN: 978-0-387-27285-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation